{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "RPD",
  "name": "Rapid7, Inc.",
  "url": "https://orbyd.app/dossiers/RPD/",
  "json_url": "https://orbyd.app/dossiers/RPD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Ex-growth cyber name (Q1 2026 rev -0.3% YoY; Q2 ARR guided to ~$820M) trading near $11 purely on a Jana-forced take-private; Goldman/JPMorgan shopping RPD to Advent/Bain/EQT. Newest sell-side PTs now cluster $9–11 at the tape as deal probability prices in — a maturing event probe into the ~2026-08-05 Q2 print, not a momentum name.",
  "invalidation_trigger": "A weekly close below $9.50 breaks the ~$10.60–11.20 take-private shelf and confirms the deal premium is bleeding toward the $9 standalone / $6.50 deep-value floor; a formal \"remain independent\" outcome to the Goldman/JPMorgan sale process ends the setup outright.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "ai-enterprise-software"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Recent-analyst PTs ($6.50 DA Davidson 2026-06-02; ~$6.67 avg of 3 newest; WallStreetZen 1Y $9.63) sit BELOW the ~$11 tape. The gap is pure deal premium and defines the downside if talks collapse.",
    "FY2026 guide (2026-05-05): revenue $836–842M, FCF $125–135M vs ~$731M market cap — sub-1x ARR, high-teens FCF yield = LBO-friendly, which is why sponsors are circling.",
    "Earnings blackout: Q2 2026 print est. ~2026-08-05. Binary M&A headlines can hit any day — size as a small event probe, not a trend trade. Not a momentum setup; RPD is a laggard decoupled from the accelerating cyber leaders.",
    "Growth is dead: Q1 2026 (2026-05-05) revenue $209.7M, -0.3% YoY; Q2 ARR guided to ~$820M from $832M. Any live thesis is the take-private, not the fundamentals.",
    "Jana Partners ~10.3% (6.76M sh, 13D 2026-02-13), settlement room to 19.9%, board seat (Kevin Galligan); disclosed buys ~$15.71 (2025-11-28). Goldman Sachs + JPMorgan running the sale; Advent/Bain/EQT early talks, Cannae possibly partnering. Deal may not happen — could stay independent.",
    "Newest sell-side (2026-07-15/21): Mizuho $11 Neutral, Truist $10 Hold, Morgan Stanley $9 Underweight. PTs migrated up from the June $6.50–6.67 fundamental floor toward the tape; the MS downgrade is the dissent that flags a poor risk/reward near $11.",
    "FY2026 guide (2026-05-05): revenue $836–842M, FCF $125–135M vs ~$731M market cap — sub-1x ARR, high-teens FCF yield = LBO-friendly, which is why sponsors circle.",
    "Earnings blackout: Q2 2026 print est. ~2026-08-05 (binary). M&A headlines can hit any day. Size as a small event probe, not a trend trade; RPD is a laggard decoupled from the accelerating cyber leaders."
  ],
  "body_markdown": "## Current Thesis\nRapid7's growth story ended several quarters ago. Q1 2026 (reported 2026-05-05) put revenue at $209.7M, down 0.3% year-over-year, ARR at $832M compounding in the low single digits, and management guiding Q2 2026 ARR *down* to roughly $820M — a sequential contraction. On a standalone basis this is an ex-growth, cash-generative security-software business, and the only reason the stock sits near $11 rather than the high single digits is the take-private process Jana Partners forced. Jana holds ~10.3% (6.76M shares, 13D 2026-02-13) with settlement room to 19.9% and a board seat (Kevin Galligan), while Goldman Sachs and JPMorgan shop the company to Advent International, Bain Capital and EQT. The fresh tell is where sell-side targets have moved: DA Davidson's $6.50 standalone floor (2026-06-02) has been overtaken by Mizuho $11 (2026-07-15), Truist $10 (2026-07-21) and Morgan Stanley $9 (2026-07-21, cut to Underweight). The desks are now marking to a deal-probability band that brackets the tape rather than to fundamentals. This is a maturing event-driven special situation into a binary Q2 print (~2026-08-05), not a momentum trade.\n\n## Bull Case\n- **LBO math the sponsors are underwriting.** FY2026 guide (2026-05-05) is $836–842M revenue and $125–135M free cash flow against a ~$731M market cap at $10.94 (2026-07-08): sub-1x market-cap-to-ARR and a high-teens FCF yield — recurring revenue, positive cash, depressed multiple, the exact profile private equity takes out.\n- **Committed activist with a path.** Jana built ~10.3% (13D 2026-02-13), disclosed buying at $15.71 (2025-11-28), won a board seat, and can accumulate to 19.9% — an owner marking fair value well above the current tape and pushing toward a sale.\n- **Bankers engaged, multiple named bidders.** Goldman Sachs and JPMorgan are running the process; Advent, Bain and EQT are in early-stage talks and Cannae Holdings is reportedly weighing a PE partnership. Several credible sponsors reduce single-bidder risk.\n- **Sell-side re-rating toward a deal.** Truist to $10 and Mizuho to $11 (2026-07-15/21) lifted targets off the June $6.50–6.67 fundamental band, narrowing the air beneath the price that the newest PTs implied only six weeks earlier.\n- **Supportive backdrop.** Second-half small-cap tape is being driven by buyouts (Benzinga small-cap roundup, 2026-07-21); event-driven names with real sponsor interest are in favor.\n\n## Bear Case\n- **The business is shrinking.** Q1 2026 revenue -0.3% YoY, product revenue roughly flat, services down, and Q2 ARR guided to ~$820M from $832M. Detection & response (~55% of ARR) grows ~7% but the legacy vulnerability-management base offsets it.\n- **A desk just moved the other way.** Morgan Stanley cut RPD to Underweight with a $9 target (2026-07-21) — with a binary print ten days out and the stock near $11, at least one desk reads the risk/reward as negative.\n- **\"May not lead to a deal.\"** Every report carries the caveat that talks collapse and Rapid7 stays independent. That headline reprices the stock to the $9 standalone / $6.50 deep-value band with no warning.\n- **Financing-cost sensitivity.** LBO debt terms cap the achievable bid; a higher-for-longer rate path compresses the premium a sponsor can pay.\n- **No trend to ride.** RPD is a range-bound laggard decoupled from the accelerating cyber leaders; there is no momentum leg here, only deal odds.\n\n## Setup & Price Structure\nRPD has built a multi-month shelf in the ~$10.60–11.20 zone off the 52-week low of $4.97, trading near $10.94 as of 2026-07-08 — coiled and range-bound rather than trending. The newest analyst targets bracket the tape almost exactly: Morgan Stanley $9, Truist $10, Mizuho $11 (all 2026-07-15/21). That tight cluster is the market pricing a deal-probability-weighted value, which leaves the tape with little standalone momentum and most of the outcome binary. There is no mania here and no peak-retail froth; the trap runs the other way. Buying the break of the shelf on the hope the deal still closes is the averaging-down mistake the playbook forbids. A clean fresh entry exists only as a small event probe near the shelf, sized for a binary, with no add on weakness.\n\n## Catalyst Calendar (next 30 days)\n\n- **Undated / any day:** M&A headline from the Goldman/JPMorgan process (Advent, Bain, EQT, Cannae). A signed take-private or a \"remain independent\" statement is the dominant catalyst and carries no fixed date.\n- **Undated:** Jana 13D/A accumulation disclosures up to the 19.9% cap — each incremental buy is a conviction signal on deal odds.\n\n## Elapsed catalysts\n\n- **~2026-08-05 (est.):** Q2 2026 earnings and updated ARR. Binary. ARR already guided to ~$820M; a further cut deepens the ex-growth problem, while any explicit process commentary is the swing factor. *(passed 4d ago)*\n\n## What Would Change Our Mind\n- **A signed take-private at a premium** (a bid in the low-to-mid teens) confirms the thesis and re-rates the stock — though at announcement most of the move is already realized.\n- **A formal \"remain independent\" / process-terminated announcement** collapses the premium toward the $9 Morgan Stanley standalone and the $6.50 DA Davidson deep-value floor; thesis dead.\n- **A weekly close below $9.50** breaks the take-private shelf and confirms the premium bleeding out, independent of any headline.\n- **Another ARR cut on the 2026-08-05 print** erodes the standalone valuation floor that limits downside if talks fail.\n- **Net-new ARR re-acceleration** (not expected near-term) would restore a fundamental leg and turn this from a pure event probe into a value-plus-catalyst name.\n\n## Correlation Notes\n- **Decoupled from cyber leaders.** RPD trades on deal odds; its beta to the accelerating cyber tape (PANW, CRWD, ZS, S) is low, so it neither confirms nor rides the theme's strength.\n- **Tied to PE financing conditions.** As an LBO candidate, RPD's premium tracks credit spreads and the rate path — higher-for-longer compresses the achievable bid; easing supports it.\n- **Take-private comp set.** Thoma Bravo's serial cyber take-privates set the valuation and sentiment comps for sub-scale security assets; RPD's deal-multiple expectations move with those precedents.\n- **Event-driven small-cap cohort.** Sentiment correlates with the broader small-cap buyout wave (Benzinga roundup, 2026-07-21) more than with software fundamentals.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-29T06:12:20+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}